Pfizer Target of Unusually Large Options Trading (NYSE:PFE)

Pfizer Inc. (NYSE:PFE) was the target of some unusual options trading activity on Monday. Stock traders acquired 144,204 call options on the stock. This represents an increase of approximately 31% compared to the typical volume of 110,032 call options.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on PFE. Citigroup increased their price target on shares of Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 6th. Berenberg Bank dropped their price target on shares of Pfizer from $28.00 to $25.00 and set a “hold” rating for the company in a research report on Thursday, May 29th. Morgan Stanley increased their price target on shares of Pfizer from $32.00 to $33.00 and gave the stock an “equal weight” rating in a research report on Wednesday, August 6th. Wall Street Zen raised shares of Pfizer from a “hold” rating to a “buy” rating in a research report on Saturday. Finally, Bank of America increased their price target on shares of Pfizer from $27.00 to $28.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 6th. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $28.12.

Pfizer Stock Performance

NYSE PFE opened at $24.12 on Wednesday. The firm has a market cap of $137.14 billion, a price-to-earnings ratio of 12.83, a PEG ratio of 0.78 and a beta of 0.55. The company has a 50 day moving average of $24.60 and a 200-day moving average of $24.18. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. Pfizer has a 1-year low of $20.92 and a 1-year high of $30.43.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.58 by $0.20. The company had revenue of $14.65 billion during the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company’s revenue was up 10.3% on a year-over-year basis. During the same quarter last year, the business posted $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, equities analysts forecast that Pfizer will post 2.95 earnings per share for the current fiscal year.

Institutional Trading of Pfizer

Several hedge funds have recently modified their holdings of PFE. Gould Capital LLC grew its stake in shares of Pfizer by 97.2% during the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 493 shares during the last quarter. GKV Capital Management Co. Inc. bought a new stake in shares of Pfizer during the first quarter valued at approximately $27,000. Curio Wealth LLC grew its stake in shares of Pfizer by 36,600.0% during the second quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 1,098 shares during the last quarter. North Capital Inc. bought a new stake in shares of Pfizer during the first quarter valued at approximately $28,000. Finally, Bayforest Capital Ltd bought a new stake in shares of Pfizer during the first quarter valued at approximately $28,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.